Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
621-640 of 991 trials

Hypochondroplasia: Vosoritide Treatment Study

We are testing a new medication, vosoritide, to see if it helps children with hypochondroplasia grow taller compared to a placebo. The study aims to evaluate its effects on growth velocity and height.

Hypochondroplasia1-2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemotePediatrics

Weight Loss in HIV: Semaglutide Study

We are investigating whether the medication semaglutide can help people living with HIV and obesity lose more weight when combined with diet and exercise. The study also looks at its effects on inflammation and overall health.

HIV and Obesity6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyInfectious Diseases

RSV Vaccine Study for Immunocompromised Adults

We are studying how well the RSV vaccine works and its safety in immunocompromised patients aged 18 and older. This includes comparing the immune response after one and two doses of the vaccine.

Respiratory Syncytial Virus (RSV)1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementInfectious DiseasesInternal MedicinePulmonology

Asthma Treatment: Tezepelumab Study

We are investigating whether tezepelumab can improve airway structure and function in patients with asthma compared to a placebo. This study will also explore its effects on lung health and asthma flare-ups.

Severe Asthma3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementAllergologyPulmonology

Chronic Spontaneous Urticaria: Barzolvolimab Study

We are investigating whether barzolvolimab can help patients with chronic spontaneous urticaria who still experience symptoms despite antihistamine treatment. The study aims to see if it reduces itching and hives compared to a placebo.

Chronic Spontaneous Urticaria1-2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementAllergologyDermatology

Cariprazine for Adolescents with Schizophrenia

We are studying the safety and tolerability of cariprazine in adolescents aged 13 to under 18 with schizophrenia. This trial aims to see how well the medication works and its impact on health-related outcomes.

Schizophrenia>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPediatricsPsychiatry

Peripheral T-Cell Lymphoma: Lacutamab with GemOx

We are studying a new treatment combining Lacutamab with GemOx for patients with relapsed or refractory peripheral T-cell lymphoma. The trial aims to evaluate its effectiveness and safety compared to GemOx alone.

Peripheral T-Cell Lymphoma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Advanced Gastric Cancer: [18F]AlF-FAPI-74 PET/CT Study

We are testing a new imaging method to improve the staging of advanced gastric cancer. This study aims to see if it can reduce the need for invasive procedures while providing accurate diagnostic information.

Advanced Gastric CancerEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal MedicineOncology

Hidradenitis Suppurativa: Remibrutinib Study

We are testing the effectiveness and safety of remibrutinib in adults with moderate to severe hidradenitis suppurativa. The study aims to see if it helps reduce symptoms like flare-ups and skin pain compared to a placebo.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Type 1 Diabetes: Diamyd Study

We are investigating whether the drug Diamyd can help preserve insulin production in adolescents and adults recently diagnosed with type 1 diabetes. The study will also look at the safety of Diamyd compared to a placebo.

Type 1 Diabetes>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementDiabetologyEndocrinology

KCNT1-Related Epilepsy: S230815 Treatment Study

We are testing a new treatment for children with KCNT1-related Developmental and Epileptic Encephalopathy. The study aims to evaluate its safety and how it may help reduce seizure activity.

KCNT1-related Developmental and Epileptic Encephalopathy1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Transfusion-Dependent β-Thalassemia: CTX001 Treatment

We are studying a new cell therapy for children with transfusion-dependent β-thalassemia to see if it can improve their condition and reduce the need for blood transfusions. The trial will also assess the safety of this treatment.

Transfusion-Dependent Thalassemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics

Type 1 Diabetes: Diamyd® Treatment Study

We are evaluating the safety and feasibility of Diamyd® injections in young people at risk for Type 1 diabetes. This study looks at how the treatment affects their immune system and progression of the disease.

Type 1 Diabetes1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyPediatrics

Rimegepant for Migraine: Effects on Obesity

We are studying how rimegepant affects migraine-related reactions in lean and obese individuals. The goal is to understand the relationship between body composition and migraine responses.

ObesityMigraine6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyNeurology

Brigatinib for Pediatric and Young Adult ALK+ Cancer

We are studying the safety and effectiveness of brigatinib in children and young adults with ALK+ Anaplastic Large Cell Lymphoma and other solid tumors. This trial aims to find the best dose and understand how the drug works in these patients.

Anaplastic Large Cell Lymphoma (ALCL)Inflammatory Myofibroblastic Tumors (IMT)Other Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPediatrics

Dupilumab for Uncontrolled Moderate to Severe Asthma

We are studying whether dupilumab can help prevent lung function decline in adults with uncontrolled moderate to severe asthma. This trial will compare its effects to a placebo over time.

AsthmaMonitoring phase (IV)6-10 visitsInvestigational MedicinesCost ReimbursementAllergologyPulmonology

Cardiovascular Disease Prevention: Personalized Statin Therapy

We are studying whether statin treatment guided by genetic risk can lower heart disease events in individuals at high risk. The trial will also look at how well patients accept this personalized approach and its effects on their health.

High Genetic Risk for Coronary Artery Disease1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Oxytocin Treatment for Autism in Children

We are studying whether multiple doses of oxytocin can improve social symptoms in children with autism and intellectual disability. The trial also looks at other behavioral changes and stress-related measurements.

Autism Spectrum Disorder6-12 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementPartially RemotePediatricsPsychiatry

Colon Cancer: Dostarlimab with CAPEOX

We are studying a new treatment combining dostarlimab with CAPEOX for people with untreated Stage III colon cancer. The goal is to see if this combination is more effective and safe compared to CAPEOX alone.

Metastatic Colon CancerEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyOncology

Multiple Sclerosis: Treatment Withdrawal Study for Older Adults

We are investigating whether stopping disease-modifying therapies is safe for people aged 55 and over with inactive relapsing-remitting multiple sclerosis. The study will help us understand its effects on relapse rates, disability, and quality of life.

Multiple Sclerosis>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurology